AbbVie’s positive momentum is largely driven by its second-quarter earnings results, which showcased the company’s successful navigation of the post-Humira loss-of-exclusivity landscape. The market responded favorably to the robust growth observed in the immunology portfolio, specifically with Skyrizi and Rinvoq. These two assets have demonstrated significant market share gains across multiple indications, effectively mitigating the revenue contraction from biosimilar competition in the adalimumab market. The ability to maintain high margins despite top-line pressure from legacy products reinforces investor confidence in management’s commercial execution and long-term transition strategy.

Beyond existing commercial assets, the company’s…